In 2019 sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these same therapy areas and regions totaled approximately $3 billion. Throughout our 2019-2029 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and region.

Table of contents

  • Biosimilars - Market Events And Forecast - Forecast Methodology And General Market Assumptions
    • Brands Included in Market Forecast
    • General Market Assumptions
      • Clinical Trials
        • Approval Times and Market Launch Delays
          • Key Regulatory Review and Launch Delay Assumptions
          • United States
          • EU5
          • Japan
        • Indication Extrapolation
          • Pharmacy-Level Substitution
            • Biosimilar Pricing
              • Reference-Brand Pricing
                • Biosimilar Adoption Rates
                  • Key Assumptions
                  • Biosimilar Adoption Rates
                  • United States
                  • EU5
                  • Japan

            Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

            Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

            Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.